Healthcare provider profile · identity verified

David M Ho, M.D.

Allopathic & Osteopathic Physicians|Family Medicine · BRYN MAWR, PA · NPI 1083856918

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show David M Ho, M.D. received $81.23 in general payments during 2025 across 4 reported records.

ABBVIE INC. accounted for 29.6% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 4 associated products.

A separate comparison found the same explicitly named product in public Medicare Part D data: Synthroid.

ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Linzess by this doctor in 2024.

ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Lumigan by this doctor in 2024.

ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Synthroid by this doctor in 2024.

Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 121 claims for Jardiance by this doctor in 2024.

Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Trulicity by this doctor in 2024.

Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Ozempic by this doctor in 2024.

Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rybelsus by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$81.23

4 reported records · 4 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
ABBVIE INC.	Unresolved — no canonical attribution shown	$24.00	29.6%	1	2025
Lilly USA, LLC	Unresolved — no canonical attribution shown	$20.67	25.4%	1	2025
Novo Nordisk Inc	Unresolved — no canonical attribution shown	$20.00	24.6%	1	2025
Amgen Inc.	Unresolved — no canonical attribution shown	$16.56	20.4%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$81.23	4

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
SYNTHROID Normalized: synthroid	Drug	ABBVIE INC.	$24.00	1	2025
Source payment records 2025-10-16 · ABBVIE INC. · $24.00 · Open Payments source
MOUNJARO Normalized: mounjaro	Drug	Lilly USA, LLC	$20.67	1	2025
Source payment records 2025-10-26 · Lilly USA, LLC · $20.67 · Open Payments source
ZEPBOUND Normalized: zepbound	Drug	Lilly USA, LLC	$20.67	1	2025
Source payment records 2025-10-26 · Lilly USA, LLC · $20.67 · Open Payments source
EVENITY Normalized: evenity	Biological	Amgen Inc.	$16.56	1	2025
Source payment records 2025-09-17 · Amgen Inc. · $16.56 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments product	Payment year	Part D brand	Part D year	Claims	Match method	Source
SYNTHROID synthroid	2025	Synthroid	2024	26 Beneficiary count suppressed	exact normalized	Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
ABBVIE INC. Exact reporting entity; no affiliate inference	2025	LINZESS open payments reported associated product	CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608	Linzess · 2024 Exact normalized brand match · 1 Part D row	71	14
ABBVIE INC. Exact reporting entity; no affiliate inference	2025	LUMIGAN open payments reported associated product	CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548	Lumigan · 2024 Exact normalized brand match · 1 Part D row	13	suppressed by CMS
ABBVIE INC. Exact reporting entity; no affiliate inference	2025	SYNTHROID open payments reported associated product	CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636	Synthroid · 2024 Exact normalized brand match · 1 Part D row	26	suppressed by CMS
Lilly USA, LLC Exact reporting entity; no affiliate inference	2025	JARDIANCE open payments reported associated product	CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557	Jardiance · 2024 Exact normalized brand match · 1 Part D row	121	20
Lilly USA, LLC Exact reporting entity; no affiliate inference	2025	TRULICITY open payments reported associated product	CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601	Trulicity · 2024 Exact normalized brand match · 1 Part D row	27	suppressed by CMS
Novo Nordisk Inc Exact reporting entity; no affiliate inference	2025	Ozempic open payments reported associated product	CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076	Ozempic · 2024 Exact normalized brand match · 1 Part D row	39	suppressed by CMS
Novo Nordisk Inc Exact reporting entity; no affiliate inference	2025	Rybelsus open payments reported associated product	CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076	Rybelsus · 2024 Exact normalized brand match · 1 Part D row	11	suppressed by CMS

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	1004	195
Amlodipine Besylate	Amlodipine Besylate	877	149
Levothyroxine Sodium	Levothyroxine Sodium	688	105
Pantoprazole Sodium	Pantoprazole Sodium	447	80
Lisinopril	Lisinopril	423	76
Furosemide	Furosemide	421	70
Gabapentin	Gabapentin	419	66
Mirtazapine	Mirtazapine	373	51
Eliquis	Apixaban	357	51
Metoprolol Succinate	Metoprolol Succinate	352	70
Losartan Potassium	Losartan Potassium	318	61
Tamsulosin Hcl	Tamsulosin Hcl	291	66
Escitalopram Oxalate	Escitalopram Oxalate	283	52
Sertraline Hcl	Sertraline Hcl	276	42
Alprazolam	Alprazolam	264	56
Trazodone Hcl	Trazodone Hcl	260	44
Quetiapine Fumarate	Quetiapine Fumarate	244	29
Metformin Hcl	Metformin Hcl	229	50
Memantine Hcl Er	Memantine Hcl	222	32
Donepezil Hcl	Donepezil Hcl	219	30
Simvastatin	Simvastatin	213	44
Omeprazole	Omeprazole	192	40
Prednisone	Prednisone	181	66
Hydrochlorothiazide	Hydrochlorothiazide	177	38
Metoprolol Tartrate	Metoprolol Tartrate	177	30
Tramadol Hcl	Tramadol Hcl	177	48
Duloxetine Hcl	Duloxetine Hcl	176	18
Valsartan	Valsartan	175	43
Potassium Chloride	Potassium Chloride	156	29
Metformin Hcl Er	Metformin Hcl	151	31
Rosuvastatin Calcium	Rosuvastatin Calcium	149	42
Lorazepam	Lorazepam	146	28
Pravastatin Sodium	Pravastatin Sodium	138	24
Clopidogrel	Clopidogrel Bisulfate	135	25
Meloxicam	Meloxicam	126	35
Famotidine	Famotidine	123	19
Jardiance	Empagliflozin	121	20
Glipizide	Glipizide	120	22
Methenamine Hippurate	Methenamine Hippurate	120	31
Triamcinolone Acetonide	Triamcinolone Acetonide	116	61
Risperidone	Risperidone	115	13
Finasteride	Finasteride	113	23
Myrbetriq	Mirabegron	112	22
Buspirone Hcl	Buspirone Hcl	101	17
Albuterol Sulfate Hfa	Albuterol Sulfate	98	32
Carvedilol	Carvedilol	98	19
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	97	60
Ezetimibe	Ezetimibe	93	18
Ibuprofen	Ibuprofen	92	26
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	92	12
Memantine Hcl	Memantine Hcl	87	11
Bupropion Xl	Bupropion Hcl	85	18
Oxybutynin Chloride Er	Oxybutynin Chloride	83	suppressed
Ondansetron Hcl	Ondansetron Hcl	82	35
Xarelto	Rivaroxaban	80	15
Clonazepam	Clonazepam	74	13
Latanoprost	Latanoprost	74	14
Temazepam	Temazepam	73	16
Diclofenac Sodium	Diclofenac Sodium	72	35
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	71	15
Linzess	Linaclotide	71	14
Aripiprazole	Aripiprazole	70	suppressed
Paroxetine Hcl	Paroxetine Hcl	68	suppressed
Breo Ellipta	Fluticasone/Vilanterol	67	13
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	67	18
Zolpidem Tartrate	Zolpidem Tartrate	66	14
Hydralazine Hcl	Hydralazine Hcl	65	18
Fluticasone Propionate	Fluticasone Propionate	64	19
Azelastine Hcl	Azelastine Hcl	63	23
Dicyclomine Hcl	Dicyclomine Hcl	62	13
Pregabalin	Pregabalin	57	suppressed
Amiodarone Hcl	Amiodarone Hcl	56	suppressed
Midodrine Hcl	Midodrine Hcl	55	suppressed
Nystatin	Nystatin	55	42
Torsemide	Torsemide	55	12
Pioglitazone Hcl	Pioglitazone Hcl	54	14
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	54	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	54	suppressed
Allopurinol	Allopurinol	53	12
Cephalexin	Cephalexin	51	32
Warfarin Sodium	Warfarin Sodium	51	suppressed
Alendronate Sodium	Alendronate Sodium	50	suppressed
Azithromycin	Azithromycin	50	40
Divalproex Sodium	Divalproex Sodium	49	suppressed
Levetiracetam	Levetiracetam	47	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	45	suppressed
Spironolactone	Spironolactone	44	14
Citalopram Hbr	Citalopram Hydrobromide	43	suppressed
Clonidine Hcl	Clonidine Hcl	43	suppressed
Oxycodone Hcl	Oxycodone Hcl	43	suppressed
Fenofibrate	Fenofibrate	42	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	42	suppressed
Glimepiride	Glimepiride	42	suppressed
Montelukast Sodium	Montelukast Sodium	42	11
Colchicine	Colchicine	41	13
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	41	suppressed
Loperamide	Loperamide Hcl	41	28
Ciprofloxacin Hcl	Ciprofloxacin Hcl	40	25
Ozempic	Semaglutide	39	suppressed
Propranolol Hcl	Propranolol Hcl	39	11
Ropinirole Hcl	Ropinirole Hcl	39	suppressed
Januvia	Sitagliptin Phosphate	38	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	37	suppressed
Atenolol	Atenolol	36	suppressed
Baclofen	Baclofen	36	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	35	26
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	35	suppressed
Labetalol Hcl	Labetalol Hcl	35	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	34	34
Doxazosin Mesylate	Doxazosin Mesylate	33	suppressed
Hydroxychloroquine Sulfate	Hydroxychloroquine Sulfate	33	suppressed
Nebivolol Hcl	Nebivolol Hcl	32	suppressed
Tresiba Flextouch U-200	Insulin Degludec	32	suppressed
Cefuroxime	Cefuroxime Axetil	31	25
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	30	suppressed
Methocarbamol	Methocarbamol	30	13
Mupirocin	Mupirocin	30	21
Ofloxacin	Ofloxacin	29	17
Farxiga	Dapagliflozin Propanediol	28	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	27	suppressed
Trulicity	Dulaglutide	27	suppressed
Valacyclovir	Valacyclovir Hcl	27	12
Novolog Flexpen	Insulin Aspart	26	suppressed
Synthroid	Levothyroxine Sodium	26	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	25	17
Solifenacin Succinate	Solifenacin Succinate	25	suppressed
Cefdinir	Cefdinir	24	11
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	24	suppressed
Divalproex Sodium Er	Divalproex Sodium	23	suppressed
Lubiprostone	Lubiprostone	23	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	22	suppressed
Amlodipine-Valsartan	Amlodipine Besylate/Valsartan	22	suppressed
Chlorhexidine Gluconate	Chlorhexidine Gluconate	22	suppressed
Diphenoxylate-Atropine	Diphenoxylate Hcl/Atropine	22	suppressed
Dorzolamide-Timolol	Dorzolamide/Timolol/Pf	22	suppressed
Glipizide Er	Glipizide	22	suppressed
Klayesta	Nystatin	22	12
Lamotrigine	Lamotrigine	22	suppressed
Olanzapine	Olanzapine	22	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	21	suppressed
Meclizine Hcl	Meclizine Hcl	21	suppressed
Novolog	Insulin Aspart	21	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	20	suppressed
Betamethasone Dipropionate	Betamethasone Dipropionate	20	suppressed
Tradjenta	Linagliptin	20	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	20	suppressed
Amlodipine-Atorvastatin	Amlodipine/Atorvastatin	19	suppressed
Digoxin	Digoxin	19	suppressed
Entresto	Sacubitril/Valsartan	19	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	19	suppressed
Metolazone	Metolazone	19	suppressed
Travoprost	Travoprost	19	suppressed
Amoxicillin	Amoxicillin	18	suppressed
Brimonidine Tartrate	Brimonidine Tartrate	18	suppressed
Irbesartan	Irbesartan	18	suppressed
Nifedipine Er	Nifedipine	18	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	18	suppressed
Pyridostigmine Bromide	Pyridostigmine Bromide	18	suppressed
Ramipril	Ramipril	18	suppressed
Silodosin	Silodosin	18	suppressed
Levemir Flexpen	Insulin Detemir	17	suppressed
Nystatin-Triamcinolone	Nystatin/Triamcinolone Acet	17	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	17	suppressed
Alfuzosin Hcl Er	Alfuzosin Hcl	16	suppressed
Autoshield Duo Pen Needle	Pen Needle,dual Safety,diabetc	16	suppressed
Benazepril Hcl	Benazepril Hcl	16	suppressed
Liothyronine Sodium	Liothyronine Sodium	16	suppressed
Nuplazid	Pimavanserin Tartrate	16	suppressed
Budesonide Dr	Budesonide	15	suppressed
Dutasteride	Dutasteride	15	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	15	suppressed
Spiriva Respimat	Tiotropium Bromide	15	suppressed
Aspirin-Dipyridamole Er	Aspirin/Dipyridamole	14	suppressed
Diazepam	Diazepam	14	suppressed
Flecainide Acetate	Flecainide Acetate	14	suppressed
Primidone	Primidone	14	suppressed
Acyclovir	Acyclovir	13	suppressed
Balsalazide Disodium	Balsalazide Disodium	13	suppressed
Celecoxib	Celecoxib	13	suppressed
Corlanor	Ivabradine Hcl	13	suppressed
Cyclosporine	Cyclosporine	13	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	13	suppressed
Erythromycin	Erythromycin Base	13	suppressed
Folic Acid	Folic Acid	13	suppressed
Levemir	Insulin Detemir	13	suppressed
Lumigan	Bimatoprost	13	suppressed
Naproxen	Naproxen	13	suppressed
Olmesartan-Amlodipine-Hctz	Olmesartan/Amlodipin/Hcthiazid	13	suppressed
Benztropine Mesylate	Benztropine Mesylate	12	suppressed
Diltiazem Hcl	Diltiazem Hcl	12	suppressed
Ipratropium-Albuterol	Ipratropium/Albuterol Sulfate	12	suppressed
Lacosamide	Lacosamide	12	suppressed
Praluent Pen	Alirocumab	12	suppressed
Venlafaxine Hcl	Venlafaxine Hcl	12	suppressed
Acetazolamide Er	Acetazolamide	11	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	11	suppressed
Ammonium Lactate	Ammonium Lactate	11	suppressed
Captopril	Captopril	11	suppressed
Combivent Respimat	Ipratropium/Albuterol Sulfate	11	suppressed
Dofetilide	Dofetilide	11	suppressed
Hydrocortisone	Hydrocortisone	11	suppressed
Methylphenidate Hcl	Methylphenidate Hcl	11	suppressed
Rasagiline Mesylate	Rasagiline Mesylate	11	suppressed
Rybelsus	Semaglutide	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$81.23 · 4 records	ABBVIE INC.	EVENITY, MOUNJARO, SYNTHROID, ZEPBOUND	7	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

What role, if any, does Synthroid play in your treatment recommendations for me?
How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error